Keywords: food folate; fortified folic acid; supplemental folic acid; risk; head and neck cancer; prospective cohort study

The impact of folate intake on the risk of head and neck cancer in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohort

Daisuke Kawakita^{*1,2,3,4}, Yuan-Chin Amy Lee^{1,2}, Lisa H Gren^{1,2}, Sandra S Buys^{2,5}, Carlo La Vecchia⁶ and Mia Hashibe^{1,2}

¹Division of Public Health, Department of Family and Preventive Medicine, University of Utah School of Medicine, Salt Lake City, UT 84108, USA; ²Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT 84108, USA; ³Department of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8602, Japan; ⁴Division of Molecular and Clinical Epidemiology, Aichi Cancer Center Research Institute, Nagoya 464-8681, Japan; ⁵Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT 84108, USA and ⁶Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan 520133, Italy

Background: Although low levels of folate leads to disturbances in DNA replication, DNA methylation and DNA repair, the association between dietary folate intake and head and neck cancer (HNC) risk remains unclear.

Methods: We evaluated the association between folate intake and HNC risk using prospective cohort data from the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial. This study included 101 700 participants and 186 cases with confirmed incident HNC. The median follow-up was 12.5 years. We estimated hazard ratios (HRs) and the corresponding 95% confidence intervals (CIs) using Cox proportional hazard model including age, sex, body mass index, education, race, tobacco smoking, alcohol drinking and total fruit and vegetable intake.

Results: Higher intake of food folate and fortified folic acid in foods was associated with a decreasing HNC risk in a dose-response manner. The HRs of highest vs the lowest quartile of intake were 0.35 (95%CI: 0.18–0.67) for food folate, and 0.49 (95%CI: 0.30–0.82) for fortified folic acid. Intakes of total folate, natural folate and supplemental folic acid were not associated with the risk of HNC and its subsites. We did not detect any interaction between smoking, drinking and food folate intake on HNC risk.

Conclusions: These findings provide evidence of the protective role of dietary folate intake on HNC risk.

In the United States, over 60 000 new head and neck cancer (HNC) cases was diagnosed, with over 16 000 patients dying from HNC in 2016, and this is the sixth most common cancer among men (Siegel *et al*, 2016). Tobacco smoking, alcohol drinking and human papilloma virus (HPV) infection for oropharyngeal cancer are established risk factors (Hashibe *et al*, 2009; Lubin *et al*, 2009;

Marur *et al*, 2010). However, the role of other environmental factors, including dietary factors, remains unclear.

Fruit and non-starchy vegetables, which are rich in minerals, antioxidants, and vitamins including folate, may decrease HNC risk (Pavia *et al*, 2006; Freedman *et al*, 2008; Lucenteforte *et al*, 2009). Folate is a water-soluble vitamin of the B complex group

*Correspondence: Dr D Kawakita; E-mail: dk200811@gmail.com

Received 12 May 2017; revised 17 August 2017; accepted 9 October 2017; published online 21 November 2017

© 2018 Cancer Research UK. All rights reserved 0007–0920/18

and plays a definite role in one-carbon metabolism, which facilitates *de novo* deoxynucleoside triphosphate synthesis and provides methyl groups required for intracellular methylation reactions (Lamprecht and Lipkin, 2003). Since folate insufficiency leads to disturbances in DNA replication, DNA methylation and DNA repair (Duthie, 1999; Kim, 1999; Choi and Mason, 2002), deficiency of folate intake may increase the risk of HNC. This issue has been evaluated by several epidemiological studies (McLaughlin *et al*, 1988; De Stefani *et al*, 1999; Negri *et al*, 2000; Weinstein *et al*, 2002; Bidoli *et al*, 2003; Pelucchi *et al*, 2003; Suzuki *et al*, 2007; Shanmugham *et al*, 2010; Aune *et al*, 2011; Tavani *et al*, 2012; Galeone *et al*, 2015), including one large-scale pooled-analysis (Galeone *et al*, 2015). Most studies reported that higher folate intake was associated with a decreased HNC risk (Negri *et al*, 2000; Weinstein *et al*, 2002; Bidoli *et al*, 2003; Pelucchi *et al*, 2003; Suzuki *et al*, 2007; Shanmugham *et al*, 2010; Aune *et al*, 2011; Tavani *et al*, 2012; Galeone *et al*, 2015) except for two studies (McLaughlin *et al*, 1988; De Stefani *et al*, 1999). Most investigations were case-control studies except for the Nurse's Health Study (Shanmugham *et al*, 2010), which however considered only the alcohol–folate interaction. Therefore, further evidence and quantification from cohort studies would aid the understanding of the relationship between folate and HNC risk.

In this study, we evaluated the association between folate intake and the risk of HNC using observational prospective data from the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial (Prorok *et al*, 2000).

MATERIALS AND METHODS

Study design and subjects. The PLCO cancer screening trial is a large-scale clinical trial designed to determine whether selected screening tests reduce deaths from prostate, lung, colorectal, and ovarian cancer (Prorok *et al*, 2000). The trial started in 1992 and ended enrolment in 2001. Approximately 155 000 participants between the ages of 55 and 74 were enrolled at 10 centres across the United States (Alabama, Michigan, Colorado, Hawaii, Wisconsin, Minnesota, Pennsylvania, Utah, Missouri, and Washington DC). Participants were individually randomised to the control arm or intervention arm in equal proportions. Participants assigned to the control arm received usual care, whereas participants assigned to the intervention arm were invited to receive screening exams for prostate, lung, colorectal, and ovarian cancers. Screening of participants ended in late 2006. Follow-up continues for up to 10 more years to determine the benefits or harms of screening tests. Written informed consent was obtained from all study participants. Ethical approval for human subject's research was obtained at each of the centres.

Assessment of lifestyle factors and head and neck cancer confirmation. Subjects randomised to either study arm (control or intervention) were eligible if they had completed the baseline questionnaire and the diet history questionnaire, which was administered to participants in both arms between 1998 and 2005 (Subar *et al*, 2000). A study update was mailed yearly to participants to ascertain and confirm cancer diagnoses. Participants were asked if they were diagnosed with cancer, which kind of cancer, date of diagnosis, hospital or clinic of diagnosis, and physician contact information. For every cancer reported, medical record abstraction included the cancer diagnosis date and the International Classification of Disease for Oncology, second version (ICD-O-2) code. Vital status was obtained by the administration of the Annual Study Update questionnaire, reports from relatives, friends, or physicians, and National Death Index plus searches. The study centres attempted to obtain a death certificate for each death. If participants were diagnosed with

cancer after study entry, which ranged from 1992 to 2001, and before completion of the dietary questionnaire, they were not eligible. HNC cases were diagnosed from enrolment completion to December 2009, the last available follow-up. Only malignant primary HNC cases were considered in the present analysis. Tumours were assigned to one of the five categories as follows: (1) oral cavity: ICD-O-2 codes C00.3 to C00.9, C02.0 to C02.3, C03.0, C03.1, C03.9, C04.0, C04.1, C04.8, C04.9, C05.0, C06.0 to C06.2, C06.8, and C06.9; (2) oropharynx: ICD-O-2 codes C01.9, C02.4, C05.1, C05.2, C09.0, C09.1, C09.8, C09.9, C10.0, C10.2–C10.4, C10.8, and C10.9; (3) hypopharynx: ICD-O-2 codes C12.9, C13.0 to C13.2, C13.8, and C13.9; (4) oral cavity or pharynx not otherwise specified (NOS): ICD-O-2 codes C02.8, C02.9, C05.8, C05.9, C14.0, C14.2, and C14.8; and (5) larynx: ICD-O-2 codes C10.1, C32.0 to C32.3 and C32.8 to C32.9. Of the 154 897 participants recruited into the PLCO study, 111 488 participants completed both the baseline questionnaire and the diet history questionnaire. Of the 111 488 participants with valid questionnaires, participants were excluded because: (1) they had cancer before entry into the PLCO study ($n = 9697$); (2) they did not have follow-up time ($n = 91$). Thus, this study included 101 700 participants, and 186 cases with confirmed incident HNC. For HNC cases, the numbers for control *vs* intervention group were: 93 *vs* 93.

The baseline questionnaire included information on age, sex, race, education, tobacco smoking, alcohol drinking, family history of cancer, medical history, weight, height and other selected lifestyle factors. Dietary data were collected using a self-administered food-frequency questionnaire, the Diet History Questionnaire, version 1.0 (National Cancer Institute, 2017), which was distributed to the control and intervention arms of the trial between 1998 and 2005 (Subar *et al*, 2000). The diet history questionnaire included portion size and frequency of consumption of 124 food item and supplement use during the past year (National Cancer Institute, 2017). Folate intake was estimated in accordance with the following five sources (Oaks *et al*, 2010): (1) natural folate (polyglutamates found naturally in food), (2) fortified folic acid (folic acid added to food), (3) food folate (a combination of natural folate and fortified folic acid), (4) supplemental folic acid (folic acid from vitamin supplements), and (5) total folate intake (a combination of food folate and supplemental folic acid). Food folate content was based on pre-folic acid fortification (1998) database information from the 1994–1996 Continuing Survey of Food Intake by Individuals (Subar *et al*, 1995). The post-folic acid grain fortification database information from the Nutrition Data System for Research (NDS-R) was used to estimate folic acid from fortified food. The NDS-R combines nutrition information from the US Department of Agriculture Nutrient Database for Standard Reference, food manufacturers, scientific literature, and other published food tables (University of Minnesota Nutrition Co-ordinating Center, NDSR descriptive overview). Supplemental folic acid use and dose were derived from recent use (current or 2 year ago) of four multivitamins (Oaks *et al*, 2010): One-a-Day (100% of the Recommended Dietary Allowance; Bayer Corp, Pittsburgh, PA, USA), a therapeutic or high-dose type ($> 100\%$ of the Recommended Dietary Allowance; e.g., Theragran; Bristol-Myers Squibb, New York, NY, USA), Stresstabs (B-complex + vitamin C; Inverness Medical Inc, Waltham, MA, USA), and B-complex. The B-complex multivitamin was assigned a 200-mcg folic acid dose, whereas the other multivitamins were assigned a 400-mcg folic acid dose.

Statistical analysis. Follow-up time was calculated from the date of entry until the occurrence of one of the following events: diagnosis of HNC, death, or the end of follow-up. We estimated hazard ratios (HRs) and the corresponding 95% confidence intervals (CIs) of HNC and its subsites for quartile categories of

folate intake using the Cox proportional hazards model. Models included adjustment for age (categorical), sex, body mass index (BMI) at interview ($\leq 24.9 \text{ kg m}^{-2}$ vs $\geq 25 \text{ kg m}^{-2}$), education ($\leq$ high school vs $\geq$ some college), race (White, non-Hispanic vs Other), pipe and cigar smoking status (never vs former vs current), pack-year cigarette smoking (never vs <20 vs ≥ 20), alcohol drinking intensity (never vs <4.1 g per day vs ≥ 4.1 g per day), non-alcohol total energy (continuous), and total fruit and vegetable intake (continuous). To test interactions, we performed likelihood-ratio tests, which compared models with and without the interaction term.

All statistical analyses were performed using the software STATA version.13 (Stata Corp, College Station, TX, USA). All tests were two-sided.

RESULTS

The median follow-up was 12.5 years. Table 1 shows the characteristics of the PLCO cohort and the HNC cases. Higher proportions of male, smokers, and drinkers were found in the HNC cases. Other characteristics showed no appreciable difference between the cohort and the HNC cases. The HNC cases consisted of 81 cases of oral cavity, 18 of oropharynx, 10 of hypopharynx, 1 of NOS, and 76 of larynx.

Table 2 gives the multivariate HRs, and the corresponding 95% CI for the various sources of folate intake on the risk of HNC and its subsites. Higher intake of food folate and fortified folic acid was associated with a decreased HNC risk in a dose-response manner. The HRs of highest vs the lowest quartile of intake were 0.35 (95% CI: 0.18–0.67) for food folate, and 0.49 (95% CI: 0.30–0.82) for fortified folic acid. Although these trends were consistent in laryngeal cancer cases, the impact of food folate or fortified folic acid were weaker than that for oral cavity and pharyngeal cancer cases, especially for fortified folic acid. Intakes of total folate, natural folate, and supplemental folic acid were not observed to be associated with the risk of HNC and its subsites, though all the HRs were below unity.

We also evaluated interactions of cigarette smoking and alcohol drinking with food folate intake on HNC risk (Figures 1 and 2). We found no significant deviation from the multiplicative model between smoking, drinking, and food folate intake on HNC risk (Figure 1: $p_{\text{interaction}}$ for smoking = 0.471; Figure 2: $p_{\text{interaction}}$ for drinking = 0.395). In a multivariate analysis, the HR of high tobacco/low food folate intake vs no tobacco/high food folate intake was 22.09, and high alcohol/low food folate intake vs no alcohol/high food folate intake was 3.57. Additionally, we performed stratified analyses between selected confounders and food folate intake on HNC risk (Figure 3). Food folate intake did not show remarkable heterogeneity by potential confounders, including age, sex, BMI and education, on HNC risk.

DISCUSSION

In this prospective cohort study, we found a favourable role of food folate and fortified folic acid intake in HNC development. This association was consistent across subsites of HNC, especially for laryngeal cancer cases. The favourable role of folate intake showed no deviation from a multiplicative model with smoking and drinking, and was consistent across strata of known confounders.

To date, nine case-control studies (McLaughlin *et al*, 1988; De Stefani *et al*, 1999; Negri *et al*, 2000; Weinstein *et al*, 2002; Bidoli *et al*, 2003; Pelucchi *et al*, 2003; Suzuki *et al*, 2007; Aune *et al*, 2011; Tavani *et al*, 2012) and one pooled analysis of case-control studies (Galeone *et al*, 2015) have evaluated the association between folate

intake and the risk of HNC or its subsites. Only one study from the USA evaluated the impact of folate intake on the risk of oral cavity and pharyngeal cancer, including 871 cases, and reported no association (McLaughlin *et al*, 1988). An Uruguayan study also reported no association between folate intake and upper aerodigestive tract (UADT) cancer risk (De Stefani *et al*, 1999). All other studies reported a favourable effect of folate intake on the risk of HNC or its subsites. In the study for Puerto Rico (Weinstein *et al*, 2002), including 341 oral cavity and pharyngeal cases, a favourable role of folate from fruit was observed, but no associations were observed in other sources. Additionally, a more recent Uruguayan study (Aune *et al*, 2011), including 283 oral cavity and pharyngeal and 281 laryngeal cases, found an interaction of folate intake with smoking status on UADT cancer risk. Smoking induces deactivation of folate coenzymes and vitamin B12 and results in folate deficiency (Heimbürger, 1992). These folate deficiency levels were also observed in buccal mucosa among smokers (Piyathilake *et al*, 1992). In addition, an Italian multi-centre study (Tavani *et al*, 2012), including 1467 oral cavity and pharyngeal and 851 laryngeal cases, reported a decreased HNC risk associated with folate intake. The OR for the highest vs the lowest of intake was 0.37 for oral cavity and pharynx, and 0.55 for larynx, with dose-response trends. In addition, the International Head and Neck Cancer Epidemiology consortium study, a large-scale pooled analysis including 5959 oral cavity and pharyngeal cases, observed that higher folate intake was associated with a decreased risk of oral cavity and pharyngeal cancer (OR: 0.65, 95%CI: 0.43–0.99 for the highest vs the lowest of quintile). This association was apparently stronger among hospital-based study than population-based study (Galeone *et al*, 2015). Additionally, six studies have investigated serum or plasma folate levels to compare between HNC cases and controls (Almadori *et al*, 2002; Raval *et al*, 2002; Almadori *et al*, 2005; Eleftheriadou *et al*, 2006; Gorgulu *et al*, 2010; Fanidi *et al*, 2015). They reported on a significant decreased serum or plasma folate level among HNC cases relative to controls. The European Prospective Investigation into Cancer and Nutrition (EPIC) study reported that higher levels of folate was associated with a decreased HNC risk in a dose-response manner (OR: 0.63, 95%CI: 0.35–1.16 for the highest vs the lowest of quintile) (Fanidi *et al*, 2015). However, this result was attenuated when cases were compared with additional unmatched controls.

Mechanisms of folate intake on HNC risk have been previously proposed. Folate deficiency contributes to the alteration of the normal methylation process and imbalance in the steady-state levels of DNA precursors, inducing aberrant DNA synthesis, stability and repair, and chromosomal changes (Lamprecht and Lipkin, 2003; Ulrich and Grady, 2010). Global and regional hypomethylation and hypermethylation within the CpG islands of specific gene promoters have been identified in HNCs (Hasegawa *et al*, 2002; Smith *et al*, 2007). In addition, this may lead to proto-oncogene activation and chromosomal instability (Smith *et al*, 2007). Folate-rich foods tend to have a high content of antioxidants, and consequently higher folate intake may be an indicator of a diet rich in fruit, vegetable, and a better general lifestyle pattern (Bosetti *et al*, 2009). However, we carefully adjusted by total fruit and vegetable intake in a multivariate analysis. In addition, we included other micronutrients, including vitamin B6, vitamin B12, vitamin C, vitamin E, and carotenoids, in multivariate analysis, and a decreased HR of food folate intake was consistent after adjustment by these factors.

Alcohol drinking induces to modification of folate level (Bailey, 1990). Alcohol drinking leads to reduced folate absorption, increased folate excretion, and inhibited methionine synthase in one-carbon metabolism (Barak *et al*, 1987; Mason and Choi, 2005). In this study, we detected no effect modification and interaction between alcohol and folate intake on HNC risk. We found two

Table 1. Characteristics of the PLCO cohort and the head and neck cancer cases

Characteristics	Cohort		Cases	
	No. of participants	%	No. of cases	%
Total	101 700		186	
Age				
≤ 59 years	34 950	35	63	34
60–64 years	31 742	31	60	32
65–69 years	22 526	22	44	24
≥ 70 years	12 482	12	19	10
Sex				
Male	49 460	49	150	81
Female	52 240	51	36	19
BMI				
≤ 24.9 kg m ⁻²	33 737	33	63	34
≥ 25.0 kg m ⁻²	66 630	66	119	64
Missing	1333	1	4	2
Education				
≤ High school	42 916	42	81	44
≥ Some college	58 587	58	105	56
Missing	197	0	0	0
Race				
White, Non-Hispanic	92 483	91	168	90
Other	9217	9	18	10
Pack-year cigarette smoking				
Never	48 544	48	36	19
< 20	19 239	19	25	13
≥ 20	32 761	32	124	67
Missing	1156	1	1	1
Alcohol drinking intensity (g per day)				
Never	27 744	28	43	23
Q1 (< 4.1)	36 976	36	43	23
Q2 (≥ 4.1)	36 980	36	100	54
Pipe smoking				
Never	86 543	85	146	78
Former	13 336	13	35	19
Current	937	1	5	3
Missing	884	1	0	0
Cigar smoking				
Never	88 217	87	147	79
Former	10 820	10	31	17
Current	1678	2	7	4
Missing	985	1	1	0
Non-alcohol total energy (kcal per day)	1670.91 ± 698.09		1767.20 ± 734.39	
Mean ± s.d.				
Total vegetable intake (g per day)	284.03 ± 186.37		263.72 ± 162.46	
Mean ± s.d.				
Total fruit intake (g per day)	273.91 ± 217.84		212.31 ± 281.97	
Mean ± s.d.				
Primary site				
Oral cavity			81	44
Oropharynx			18	10
Hypopharynx			10	5
NOS			1	0
Larynx			76	41

Abbreviations: BMI = body mass index; NOS = oral cavity or pharynx not otherwise specified; PLCO = prostate, lung, colorectal, and ovarian cancer screening trial; s.d. = standard deviation.

studies which evaluated the interaction between alcohol drinking and folate intake on HNC risk (Shanmugham *et al*, 2010; Matsuo *et al*, 2012). The Nurse's Health Study, a prospective cohort of 87 621 women and 147 incident oral cancer cases, observed an interaction between alcohol and folate intake (P -value = 0.02). The relative risk of highest alcohol drinking and low folate intake *vs* never drinking and high folate intake was 3.36 (95% CI: 1.57–7.20). Since our highest tertile of alcohol drinking was relatively low, we might explain this inconsistency in this study.

We found no association with supplemental folic acid on HNC risk. A recent meta-analysis, including 13 randomised trials of folic

acid supplementation and almost 50 000 individual data, reported that folic acid supplementation does not substantially increase incidence of site-specific cancer during the first 5 years of supplementation (Vollset *et al*, 2013). However, dietary fortification involves doses of folic acid that are an order of magnitude lower than the doses studied in these trials. In addition, our data on supplemental folic acid were only derived from recent use (current or 2 year ago). But, our findings are also consistent with a previous report on pancreatic cancer in PLCO study (Oaks *et al*, 2010).

Our study has several strengths. With the prospective design, the questionnaire data were collected before cancer diagnosis.

Table 2. Dietary folate intake and the risk of head and neck cancer or subsites in the PLCO cohort

		Head and neck				Oral cavity and Pharynx				Larynx			
Nutrients	Cohort	Cases	HR ^a	95% CI	P-value	Cases	HR ^a	95% CI	P-value	Cases	HR ^a	95% CI	P-value
Total folate (μg per day)													
Q1 (<375.91)	25424	59	1.00	—	—	35	1.00	—	—	24	1.00	—	—
Q2 (≥375.91 to <611.80)	25426	52	0.91	0.62–1.35	0.643	24	0.65	0.38–1.12	0.119	27	1.33	0.75–2.38	0.329
Q3 (≥611.80 to <780.26)	25422	36	0.71	0.47–1.09	0.121	25	0.74	0.44–1.26	0.268	11	0.64	0.31–1.33	0.234
Q4 (≥780.26)	25428	39	0.72	0.45–1.16	0.183	25	0.64	0.35–1.18	0.157	14	0.85	0.40–1.82	0.676
P _{trend}				0.090				0.220				0.261	
Food folate (μg per day)													
Q1 (<261.36)	25425	61	1.00	—	—	30	1.00	—	—	30	1.00	—	—
Q2 (≥261.36 to <350.41)	25422	33	0.47	0.30–0.73	0.001	22	0.65	0.36–1.16	0.143	11	0.30	0.15–0.63	0.001
Q3 (≥350.41 to <461.90)	25427	54	0.64	0.41–1.01	0.056	32	0.83	0.45–1.50	0.532	22	0.50	0.25–1.00	0.051
Q4 (≥461.90)	25426	38	0.35	0.18–0.67	0.002	25	0.52	0.23–1.22	0.132	13	0.21	0.07–0.62	0.005
P _{trend}				0.009				0.265				0.013	
Natural folate (μg per day)													
Q1 (<170.22)	25425	51	1.00	—	—	29	1.00	—	—	21	1.00	—	—
Q2 (≥170.22 to <228.77)	25422	45	0.89	0.57–1.37	0.592	29	0.91	0.52–1.59	0.746	16	0.92	0.45–1.87	0.818
Q3 (≥228.77 to <304.99)	25426	47	0.93	0.56–1.55	0.788	24	0.70	0.36–1.35	0.287	23	1.55	0.70–3.40	0.279
Q4 (≥304.99)	25427	43	0.88	0.43–1.79	0.723	27	0.69	0.28–1.71	0.425	16	1.41	0.46–4.28	0.548
P _{trend}				0.772				0.309				0.331	
Fortified folic acid (μg per day)													
Q1 (<71.20)	25421	49	1.00	—	—	25	1.00	—	—	23	1.00	—	—
Q2 (≥71.20 to <109.89)	25428	47	0.91	0.61–1.38	0.665	25	0.96	0.54–1.68	0.877	22	0.90	0.50–1.65	0.744
Q3 (≥109.89 to <163.35)	25421	55	0.95	0.63–1.44	0.810	35	1.22	0.70–2.11	0.482	20	0.72	0.38–1.39	0.330
Q4 (≥163.35)	25430	35	0.49	0.30–0.82	0.006	24	0.70	0.37–1.35	0.290	11	0.32	0.14–0.73	0.007
P _{trend}				0.014				0.473				0.008	
Supplemental folic acid (μg per day)													
Q1 (=0)	38080	88	1.00	—	—	53	1.00	—	—	35	1.00	—	—
Q2 (≥0 to <400)	15767	26	0.86	0.56–1.34	0.513	11	0.63	0.33–1.18	0.148	14	1.26	0.68–2.35	0.468
Q3 (≥400)	47853	72	0.81	0.59–1.11	0.196	44	0.75	0.50–1.12	0.155	27	0.89	0.53–1.47	0.644
P _{trend}				0.194				0.153				0.669	

Abbreviations: CI = confidence interval; HR = hazard ratios; PLCO = prostate, lung, colorectal, and ovarian cancer screening trial.

^aAdjusted by age, sex, body mass index, education level, race/ethnicity, pipe smoking status, cigar smoking status, pack-year cigarette smoking, alcohol drinking intensity, non-alcohol total energy, total vegetable and fruit intake.

Abbreviations: CI = confidence interval; HR = hazard ratios; PLCO = prostate, lung, colorectal, and ovarian cancer screening trial.

^aAdjusted by age, sex, body mass index, education level, race/ethnicity, pipe smoking status, cigar smoking status, pack-year cigarette smoking, alcohol drinking intensity, non-alcohol total energy, total vegetable and fruit intake.

Figure 1. Hazard ratios (HRs) of head and neck cancer, and corresponding confidence intervals (95% CIs), according to pack-year of cigarette smoking and food folate intake (μg per day). The HRs were derived from Cox proportional hazard models, adjusting for age, sex, body mass index, education, race/ethnicity, pipe smoking status, cigar smoking status, pack-year cigarette smoking, alcohol drinking intensity, non-alcohol total energy, total vegetable and fruit intake. The number of cases and controls within each category was indicated below the corresponding HR as: 'number of cases: number of cohorts'. We found no interaction between smoking and food folate intake on HNC risk.

Figure 2. Hazard ratios (HRs) of head and neck cancer, and corresponding confidence intervals (95% CIs), according to alcohol drinking intensity (g per day) and food folate intake (μg per day). The HRs were derived from Cox proportional hazard models, adjusting for age, sex, body mass index, education, race/ethnicity, pipe smoking status, cigar smoking status, pack-year cigarette smoking, alcohol drinking intensity, non-alcohol total energy, total vegetable and fruit intake. The number of cases and controls within each category was indicated below the corresponding HR as: ‘number of cases: number of cohorts’. We found no interaction between drinking, and food folate intake on HNC risk.

Figure 3. Impact of higher quartiles of food folate intake (Q2, ≥261.36 to <350.41 μg per day; Q3, ≥350.41 to <460.90 μg per day; Q4, ≥460.90 μg per day) on HNC risk compared to the lowest quartiles of food folate intake (Q1, <261.36 μg per day) according to selected covariates. The hazard ratios (HRs) were estimated from Cox proportional hazard models, adjusting for age, sex, body mass index, education, race/ethnicity, pipe smoking status, cigar smoking status, pack-year cigarette smoking, alcohol drinking intensity, non-alcohol total energy, total vegetable and fruit intake. We found no interaction between selected covariates and total fibre intake on HNC risk.

Thus, we can exclude the possibility of recall bias due to cancer outcome. We carefully adjusted for known confounders associated with HNC risk, including tobacco smoking, alcohol drinking and the intake of total fruit and vegetable. In addition, we were able to evaluate several types of dietary folate intake including fortified and supplemental folic acid.

Our sample size of HNC cases was limited; thus, statistical power was not so strong particularly for subsite analysis. However, this is the largest prospective cohort study to date. The time elapsed between exposure data collection and disease incidence may lead to some underestimate of the real association. We were unable to consider possible changes in diet between interview and diagnosis. We did not have information on relevant gene variants in one-carbon metabolism and HPV infection. Since these alleles are randomly assigned at the time of gamete formation, the distribution of alleles in our cohort is unlikely to confound the protective role of folate intake on HNC development (Smith and Ebrahim, 2003). In addition, since we would not expect HPV infection to be related specifically to folate intake, HPV infection status does not meet the properties of a confounder. In any case our data set included only 18 oropharyngeal cancers which was associated with HPV infection. When we divided HNC cases into subsites, we also considered the impact of folate intake on oropharyngeal cases only. We found a similar decreased trend on oropharyngeal cases.

In summary, our findings provided evidence of the protective role of dietary folate on HNC development.

ACKNOWLEDGEMENTS

We thank the NIH PLCO study group for allowing us to use the data. This work was supported by contracts from the Division of Cancer Prevention, National Cancer Institute, NIH, DHHS under Award Number N01-CN-25524 and by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR001067. In addition, this work was supported by JSPS Grant-in-Aid for Young Scientists (B) to D. Kawakita (No. 15K21283), and by Italian Foundation for Cancer Research (FIRC) to C. La Vecchia.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

- Almadori G, Bussu F, Galli J, Cadoni G, Zappacosta B, Persichilli S, Minucci A, Giardina B (2002) Serum folate and homocysteine levels in head and neck squamous cell carcinoma. *Cancer* **94**(4): 1006–1011.
- Almadori G, Bussu F, Galli J, Cadoni G, Zappacosta B, Persichilli S, Minucci A, Giardina B, Maurizi M (2005) Serum levels of folate, homocysteine, and vitamin B12 in head and neck squamous cell carcinoma and in laryngeal leukoplakia. *Cancer* **103**(2): 284–292.
- Aune D, Deneo-Pellegrini H, Ronco AL, Boffetta P, Acosta G, Mendilaharsu M, De Stefani E (2011) Dietary folate intake and the risk of 11 types of cancer: a case-control study in Uruguay. *Ann Oncol* **22**(2): 444–451.
- Bailey LB (1990) Folate status assessment. *J Nutr* **120**(Suppl 11): 1508–1511.
- Barak AJ, Beckenhauer HC, Tuma DJ, Badakhsh S (1987) Effects of prolonged ethanol feeding on methionine metabolism in rat liver. *Biochem Cell Biology* = *Biochim Biol Cell* **65**(3): 230–233.
- Bidoli E, Bosetti C, La Vecchia C, Levi F, Parpinel M, Talamini R, Negri E, Maso LD, Franceschi S (2003) Micronutrients and laryngeal cancer risk in Italy and Switzerland: a case-control study. *Cancer Causes Control* **14**(5): 477–484.
- Bosetti C, Pelucchi C, La Vecchia C (2009) Diet and cancer in Mediterranean countries: carbohydrates and fats. *Publ Health Nutr* **12**(9A): 1595–1600.
- Choi SW, Mason JB (2002) Folate status: effects on pathways of colorectal carcinogenesis. *J Nutr* **132**(8 Suppl): 2413S–2418S.
- De Stefani E, Ronco A, Mendilaharsu M, Deneo-Pellegrini H (1999) Diet and risk of cancer of the upper aerodigestive tract – II. Nutrients. *Oral Oncol* **35**(1): 22–26.
- Duthie SJ (1999) Folic acid deficiency and cancer: mechanisms of DNA instability. *Br Med Bull* **55**(3): 578–592.
- Eleftheriadou A, Chalastras T, Ferekidou E, Yiotakis I, Kyriou L, Tzagarakis M, Ferekidis E, Kandiloros D (2006) Association between squamous cell carcinoma of the head and neck and serum folate and homocysteine. *Anticancer Res* **26**(3B): 2345–2348.
- Fanidi A, Relton C, Ueland PM, Middttun O, Vollset SE, Travis RC, Trichopoulou A, Lagiou P, Trichopoulos D, Bueno-de-Mesquita HB, Ros M, Boeing H, Tumino R, Panico S, Palli D, Sieri S, Vineis P, Sanchez MJ, Huerta JM, Barricarte Gurtea A, Lujan-Barroso L, Quiros JR, Tjonneland A, Halkjaer J, Boutron-Ruault MC, Clavel-Chapelon F, Cadeau C, Weiderpass E, Johansson M, Riboli E, Brennan P, Johansson M (2015) A prospective study of one-carbon metabolism biomarkers and cancer of the head and neck and esophagus. *Int J Cancer* **136**(4): 915–927.
- Freedman ND, Park Y, Subar AF, Hollenbeck AR, Leitzmann MF, Schatzkin A, Abnet CC (2008) Fruit and vegetable intake and head and neck cancer risk in a large United States prospective cohort study. *Int J Cancer* **122**(10): 2330–2336.
- Galeone C, Edefonti V, Parpinel M, Leoncini E, Matsuo K, Talamini R, Olshan AF, Zevallos JP, Winn DM, Jayaprakash V, Moysich K, Zhang ZF, Morgenstern H, Levi F, Bosetti C, Kelsey K, McClean M, Schantz S, Yu GP, Boffetta P, Lee YC, Hashibe M, La Vecchia C, Boccia S (2015) Folate intake and the risk of oral cavity and pharyngeal cancer: a pooled analysis within the International Head and Neck Cancer Epidemiology Consortium. *Int J Cancer* **136**(4): 904–914.
- Gorgulu O, Selcuk T, Ozdemir S, Sayar C, Beyazit Y, Akbas Y (2010) Evaluation of the roles of serum vitamin B(12), folate and homocysteine levels in laryngeal squamous cell carcinoma. *J Int Med Res* **38**(6): 2047–2052.
- Hasegawa M, Nelson HH, Peters E, Ringstrom E, Posner M, Kelsey KT (2002) Patterns of gene promoter methylation in squamous cell cancer of the head and neck. *Oncogene* **21**(27): 4231–4236.
- Hashibe M, Brennan P, Chuang SC, Boccia S, Castellsague X, Chen C, Curado MP, Dal Maso L, Daudt AW, Fabianova E, Fernandez L, Wunsch-Filho V, Franceschi S, Hayes RB, Herrero R, Kelsey K, Koifman S, La Vecchia C, Lazarus P, Levi F, Lence JJ, Mates D, Matos E, Menezes A, McClean MD, Muscat J, Eluf-Neto J, Olshan AF, Purdue M, Rudnai P, Schwartz SM, Smith E, Sturgis EM, Szeszenia-Dabrowska N, Talamini R, Wei Q, Winn DM, Shangina O, Pilarska A, Zhang ZF, Ferro G, Berthiller J, Boffetta P (2009) Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. *Cancer Epidemiol Biomarkers Prev* **18**(2): 541–550.
- Heimbürger DC (1992) Localized deficiencies of folic acid in aerodigestive tissues. *Ann NY Acad Sci* **669**: 87–95. discussion 95–96.
- Kim YI (1999) Folate and carcinogenesis: evidence, mechanisms, and implications. *J Nutr Biochem* **10**(2): 66–88.
- Lamprecht SA, Lipkin M (2003) Chemoprevention of colon cancer by calcium, vitamin D and folate: molecular mechanisms. *Nat Rev Cancer* **3**(8): 601–614.
- Lubin JH, Purdue M, Kelsey K, Zhang ZF, Winn D, Wei Q, Talamini R, Szeszenia-Dabrowska N, Sturgis EM, Smith E, Shangina O, Schwartz SM, Rudnai P, Neto JE, Muscat J, Morgenstern H, Menezes A, Matos E, Mates IN, Lissowska J, Levi F, Lazarus P, La Vecchia C, Koifman S, Herrero R, Franceschi S, Wunsch-Filho V, Fernandez L, Fabianova E, Daudt AW, Maso LD, Curado MP, Chen C, Castellsague X, Brennan P, Boffetta P, Hashibe M, Hayes RB (2009) Total exposure and exposure rate effects for alcohol and smoking and risk of head and neck cancer: a pooled analysis of case-control studies. *Am J Epidemiol* **170**(8): 937–947.
- Lucenteforte E, Garavello W, Bosetti C, La Vecchia C (2009) Dietary factors and oral and pharyngeal cancer risk. *Oral Oncol* **45**(6): 461–467.
- Marur S, D'Souza G, Westra WH, Forastiere AA (2010) HPV-associated head and neck cancer: a virus-related cancer epidemic. *Lancet Oncol* **11**(8): 781–789.
- Mason JB, Choi SW (2005) Effects of alcohol on folate metabolism: implications for carcinogenesis. *Alcohol* **35**(3): 235–241.

- Matsuo K, Rossi M, Negri E, Oze I, Hosono S, Ito H, Watanabe M, Yatabe Y, Hasegawa Y, Tanaka H, Tajima K, La Vecchia C (2012) Folate, alcohol, and aldehyde dehydrogenase 2 polymorphism and the risk of oral and pharyngeal cancer in Japanese. *Eur J Cancer Prev* **21**(2): 193–198.
- McLaughlin JK, Gridley G, Block G, Winn DM, Preston-Martin S, Schoenberg JB, Greenberg RS, Stemhagen A, Austin DF, Ershow AG *et al.* (1988) Dietary factors in oral and pharyngeal cancer. *J Natl Cancer Inst* **80**(15): 1237–1243.
- National Cancer Institute (2017) Diet history questionnaire. Risk factor monitoring and methods. Version current 30 Nov 2016. Internet <http://www.riskfactor.cancer.gov/DHQ> (accessed 30 November 2016).
- Negri E, Franceschi S, Bosetti C, Levi F, Conti E, Parpinel M, La Vecchia C (2000) Selected micronutrients and oral and pharyngeal cancer. *Int J Cancer* **86**(1): 122–127.
- Oaks BM, Dodd KW, Meinhold CL, Jiao L, Church TR, Stolzenberg-Solomon RZ (2010) Folate intake, post-folic acid grain fortification, and pancreatic cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. *Am J Clin Nutr* **91**(2): 449–455.
- Pavia M, Pileggi C, Nobile CG, Angelillo IF (2006) Association between fruit and vegetable consumption and oral cancer: a meta-analysis of observational studies. *Am J Clin Nutr* **83**(5): 1126–1134.
- Pelucchi C, Talamini R, Negri E, Levi F, Conti E, Franceschi S, La Vecchia C (2003) Folate intake and risk of oral and pharyngeal cancer. *Ann Oncol* **14**(11): 1677–1681.
- Piyathilake CJ, Hine RJ, Dasanayake AP, Richards EW, Freeberg LE, Vaughn WH, Krumdieck CL (1992) Effect of smoking on folate levels in buccal mucosal cells. *Int J Cancer* **52**(4): 566–569.
- Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, Fogel R, Gelmann EP, Gilbert F, Hasson MA, Hayes RB, Johnson CC, Mandel JS, Oberman A, O'Brien B, Oken MM, Rafla S, Reding D, Rutt W, Weissfeld JL, Yokochi L, Gohagan JK, Prostate LC. Ovarian Cancer Screening Trial Project T (2000) Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. *Controlled Clinical Trials* **21**(6 Suppl): 273S–309S.
- Raval GN, Sainger RN, Rawal RM, Patel JB, Patel BP, Jha FP, Patel DD, Patel PS (2002) Vitamin B(12) and folate status in head and neck cancer. *Asian Pacific J Cancer Prev* **3**(2): 155–162.
- Shanmugham JR, Zavras AI, Rosner BA, Giovannucci EL (2010) Alcohol–folate interactions in the risk of oral cancer in women: a prospective cohort study. *Cancer Epidemiol Biomarkers Prev* **19**(10): 2516–2524.
- Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. *CA: Cancer J Clin* **66**(1): 7–30.
- Smith GD, Ebrahim S (2003) 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? *Int J Epidemiol* **32**(1): 1–22.
- Smith IM, Mydlarz WK, Mithani SK, Califano JA (2007) DNA global hypomethylation in squamous cell head and neck cancer associated with smoking, alcohol consumption and stage. *Int J Cancer* **121**(8): 1724–1728.
- Subar AF, Midthune D, Kulldorff M, Brown CC, Thompson FE, Kipnis V, Schatzkin A (2000) Evaluation of alternative approaches to assign nutrient values to food groups in food frequency questionnaires. *Am J Epidemiol* **152**(3): 279–286.
- Subar AF, Thompson FE, Smith AF, Jobe JB, Ziegler RG, Potischman N, Schatzkin A, Hartman A, Swanson C, Kruse L *et al.* (1995) Improving food frequency questionnaires: a qualitative approach using cognitive interviewing. *J Am Dietetic Assoc* **95**: 781–788. quiz 789–790.
- Suzuki T, Matsuo K, Hasegawa Y, Hiraki A, Wakai K, Hirose K, Saito T, Sato S, Ueda R, Tajima K (2007) One-carbon metabolism-related gene polymorphisms and risk of head and neck squamous cell carcinoma: case-control study. *Cancer Sci* **98**(9): 1439–1446.
- Tavani A, Malerba S, Pelucchi C, Dal Maso L, Zucchetto A, Serraino D, Levi F, Montella M, Franceschi S, Zamboni A, La Vecchia C (2012) Dietary folates and cancer risk in a network of case-control studies. *Ann Oncol* **23**(10): 2737–2742.
- Ulrich CM, Grady WM (2010) Linking epidemiology to epigenomics – where are we today? *Cancer Prev Res* **3**(12): 1505–1508.
- University of Minnesota Nutrition Co-ordinating Center. NDSR descriptive overview. Version current 30 November 2016. Internet <http://www.ncc.umn.edu/> (accessed 30 November 2016).
- Vollset SE, Clarke R, Lewington S, Ebbing M, Halsey J, Lonn E, Armitage J, Manson JE, Hankey GJ, Spence JD, Galan P, Bona KH, Jamison R, Gaziano JM, Guarino P, Baron JA, Logan RF, Giovannucci EL, den Heijer M, Ueland PM, Bennett D, Collins R, Peto R. Collaboration BVTT (2013) Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50,000 individuals. *Lancet* **381**(9871): 1029–1036.
- Weinstein SJ, Gridley G, Harty LC, Diehl SR, Brown LM, Winn DM, Bravo-Otero E, Hayes RB (2002) Folate intake, serum homocysteine and methylenetetrahydrofolate reductase (MTHFR) C677T genotype are not associated with oral cancer risk in Puerto Rico. *J Nutr* **132**(4): 762–767.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.